Alicia Katherine Morgans, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 96 | 2024 | 11122 | 8.180 |
Why?
|
Androgen Antagonists | 39 | 2024 | 1410 | 6.730 |
Why?
|
Quality of Life | 28 | 2024 | 13367 | 1.610 |
Why?
|
Urogenital Neoplasms | 3 | 2020 | 131 | 1.410 |
Why?
|
Nitriles | 7 | 2024 | 971 | 1.380 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2024 | 783 | 1.270 |
Why?
|
Phenylthiohydantoin | 5 | 2024 | 205 | 1.260 |
Why?
|
Urinary Bladder Neoplasms | 6 | 2024 | 2223 | 1.250 |
Why?
|
Neoplasm Metastasis | 13 | 2024 | 4915 | 1.100 |
Why?
|
Prostate-Specific Antigen | 13 | 2024 | 2469 | 1.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2024 | 11742 | 0.950 |
Why?
|
Benzamides | 5 | 2024 | 1370 | 0.940 |
Why?
|
Male | 131 | 2024 | 360842 | 0.940 |
Why?
|
Androgen Receptor Antagonists | 5 | 2024 | 125 | 0.910 |
Why?
|
Antineoplastic Agents, Hormonal | 8 | 2024 | 1520 | 0.790 |
Why?
|
Drug Interactions | 2 | 2024 | 1416 | 0.790 |
Why?
|
Hot Flashes | 1 | 2023 | 330 | 0.730 |
Why?
|
Humans | 149 | 2024 | 761572 | 0.680 |
Why?
|
Medical Oncology | 8 | 2023 | 2321 | 0.680 |
Why?
|
Prostatectomy | 8 | 2024 | 1824 | 0.670 |
Why?
|
Urologic Neoplasms | 1 | 2023 | 314 | 0.650 |
Why?
|
Cardiovascular Diseases | 10 | 2024 | 15501 | 0.650 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2019 | 48 | 0.640 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 8002 | 0.640 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2018 | 37 | 0.620 |
Why?
|
Bone Density | 6 | 2023 | 3551 | 0.600 |
Why?
|
Receptors, Androgen | 7 | 2024 | 1079 | 0.600 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13642 | 0.590 |
Why?
|
Hormones | 7 | 2023 | 869 | 0.570 |
Why?
|
Decision Making | 5 | 2023 | 3929 | 0.560 |
Why?
|
Cisplatin | 3 | 2023 | 1652 | 0.520 |
Why?
|
Germ-Line Mutation | 5 | 2023 | 1858 | 0.520 |
Why?
|
Toremifene | 2 | 2012 | 24 | 0.500 |
Why?
|
Gonadotropin-Releasing Hormone | 5 | 2024 | 1148 | 0.500 |
Why?
|
Patient Participation | 2 | 2024 | 1445 | 0.490 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 491 | 0.490 |
Why?
|
Drug Therapy | 1 | 2018 | 503 | 0.480 |
Why?
|
Osteoporosis | 3 | 2020 | 1606 | 0.480 |
Why?
|
Urinary Incontinence | 5 | 2024 | 489 | 0.470 |
Why?
|
Metformin | 1 | 2022 | 906 | 0.460 |
Why?
|
Aged | 41 | 2024 | 169310 | 0.460 |
Why?
|
Leuprolide | 3 | 2024 | 312 | 0.450 |
Why?
|
Molecular Targeted Therapy | 4 | 2022 | 2811 | 0.440 |
Why?
|
Treatment Outcome | 26 | 2024 | 64684 | 0.430 |
Why?
|
Neoplasms | 11 | 2024 | 22173 | 0.430 |
Why?
|
Feasibility Studies | 1 | 2023 | 5247 | 0.420 |
Why?
|
Androgens | 5 | 2024 | 1286 | 0.410 |
Why?
|
Central Nervous System | 1 | 2019 | 1336 | 0.410 |
Why?
|
Fractures, Bone | 3 | 2023 | 2046 | 0.390 |
Why?
|
Survivors | 9 | 2024 | 2371 | 0.380 |
Why?
|
Taxoids | 2 | 2024 | 668 | 0.340 |
Why?
|
Motivation | 1 | 2019 | 2006 | 0.340 |
Why?
|
Hypertension, Renal | 1 | 2009 | 135 | 0.330 |
Why?
|
Cognition | 4 | 2022 | 6992 | 0.330 |
Why?
|
Pyrimidinones | 4 | 2024 | 385 | 0.320 |
Why?
|
Prostate | 8 | 2024 | 1773 | 0.310 |
Why?
|
Phenylurea Compounds | 4 | 2024 | 529 | 0.310 |
Why?
|
Neoplasm Staging | 11 | 2024 | 11121 | 0.300 |
Why?
|
Research Design | 1 | 2024 | 6180 | 0.300 |
Why?
|
Cognition Disorders | 1 | 2022 | 3980 | 0.300 |
Why?
|
Early Detection of Cancer | 4 | 2022 | 3201 | 0.290 |
Why?
|
Bone Neoplasms | 4 | 2022 | 2529 | 0.290 |
Why?
|
Diabetes Complications | 1 | 2014 | 1315 | 0.290 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8528 | 0.290 |
Why?
|
Piperazines | 3 | 2024 | 2523 | 0.290 |
Why?
|
Depression | 3 | 2020 | 8124 | 0.280 |
Why?
|
Palliative Care | 2 | 2019 | 3598 | 0.280 |
Why?
|
Erectile Dysfunction | 3 | 2015 | 444 | 0.280 |
Why?
|
Testosterone | 4 | 2024 | 2472 | 0.270 |
Why?
|
United States | 21 | 2024 | 72335 | 0.270 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 531 | 0.260 |
Why?
|
Dementia | 1 | 2020 | 2689 | 0.250 |
Why?
|
Urology | 2 | 2020 | 400 | 0.250 |
Why?
|
Adenocarcinoma | 3 | 2018 | 6346 | 0.240 |
Why?
|
Disease Management | 5 | 2019 | 2508 | 0.240 |
Why?
|
Thiohydantoins | 1 | 2024 | 19 | 0.240 |
Why?
|
Referral and Consultation | 3 | 2019 | 3600 | 0.230 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 795 | 0.230 |
Why?
|
Hospitalization | 1 | 2024 | 10721 | 0.230 |
Why?
|
Genetic Testing | 4 | 2021 | 3537 | 0.230 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2024 | 82 | 0.220 |
Why?
|
Bone and Bones | 1 | 2014 | 2568 | 0.220 |
Why?
|
Immunotherapy | 3 | 2018 | 4652 | 0.220 |
Why?
|
Aged, 80 and over | 14 | 2024 | 58986 | 0.210 |
Why?
|
Cardiovascular System | 2 | 2021 | 834 | 0.210 |
Why?
|
Watchful Waiting | 3 | 2024 | 491 | 0.210 |
Why?
|
Middle Aged | 26 | 2024 | 220920 | 0.210 |
Why?
|
Disease-Free Survival | 4 | 2022 | 6815 | 0.210 |
Why?
|
Orchiectomy | 3 | 2020 | 463 | 0.210 |
Why?
|
Radiotherapy | 3 | 2024 | 1499 | 0.200 |
Why?
|
Budgets | 1 | 2024 | 230 | 0.200 |
Why?
|
Continuity of Patient Care | 2 | 2020 | 1069 | 0.200 |
Why?
|
Risk Assessment | 8 | 2023 | 23996 | 0.200 |
Why?
|
Phthalazines | 2 | 2024 | 383 | 0.200 |
Why?
|
5-Methylcytosine | 1 | 2022 | 148 | 0.200 |
Why?
|
Prednisone | 4 | 2023 | 1563 | 0.200 |
Why?
|
Internal-External Control | 1 | 2023 | 358 | 0.190 |
Why?
|
Androstenes | 2 | 2021 | 181 | 0.190 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2020 | 1784 | 0.170 |
Why?
|
Antigens, Surface | 1 | 2024 | 1606 | 0.170 |
Why?
|
Lutetium | 3 | 2024 | 38 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17904 | 0.160 |
Why?
|
Genomics | 3 | 2021 | 5821 | 0.160 |
Why?
|
Heterocyclic Compounds, 1-Ring | 3 | 2024 | 68 | 0.160 |
Why?
|
Quality Indicators, Health Care | 2 | 2022 | 1792 | 0.160 |
Why?
|
Prognosis | 11 | 2024 | 29629 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2020 | 3514 | 0.160 |
Why?
|
Patient Selection | 3 | 2023 | 4244 | 0.160 |
Why?
|
Personal Satisfaction | 1 | 2023 | 644 | 0.150 |
Why?
|
Consensus | 4 | 2022 | 3123 | 0.150 |
Why?
|
Survival Rate | 5 | 2024 | 12725 | 0.150 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 601 | 0.150 |
Why?
|
Diabetes Mellitus | 3 | 2016 | 5841 | 0.150 |
Why?
|
Retrospective Studies | 10 | 2024 | 80646 | 0.140 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 764 | 0.140 |
Why?
|
Retinoblastoma Protein | 1 | 2021 | 672 | 0.140 |
Why?
|
SEER Program | 3 | 2024 | 1450 | 0.140 |
Why?
|
Dipeptides | 3 | 2024 | 391 | 0.140 |
Why?
|
Cohort Studies | 7 | 2024 | 41493 | 0.140 |
Why?
|
Pyrazoles | 2 | 2024 | 2009 | 0.140 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7391 | 0.140 |
Why?
|
Publishing | 1 | 2024 | 833 | 0.140 |
Why?
|
Vascular Neoplasms | 1 | 2018 | 166 | 0.130 |
Why?
|
Gonadal Steroid Hormones | 1 | 2020 | 702 | 0.130 |
Why?
|
Biomedical Research | 2 | 2024 | 3429 | 0.130 |
Why?
|
Delphi Technique | 2 | 2022 | 846 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 953 | 0.130 |
Why?
|
Risk Factors | 11 | 2024 | 74213 | 0.130 |
Why?
|
Osteoporotic Fractures | 1 | 2020 | 411 | 0.130 |
Why?
|
Uterine Artery Embolization | 1 | 2016 | 59 | 0.130 |
Why?
|
Carboplatin | 1 | 2018 | 794 | 0.130 |
Why?
|
Balloon Occlusion | 1 | 2016 | 125 | 0.120 |
Why?
|
Prospective Studies | 9 | 2024 | 54426 | 0.120 |
Why?
|
Meta-Analysis as Topic | 1 | 2019 | 1380 | 0.120 |
Why?
|
Research | 1 | 2023 | 1982 | 0.120 |
Why?
|
Kidney Transplantation | 1 | 2009 | 4235 | 0.120 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2651 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2024 | 857 | 0.110 |
Why?
|
Comprehension | 1 | 2019 | 621 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2022 | 2330 | 0.110 |
Why?
|
Hormone Replacement Therapy | 1 | 2019 | 751 | 0.110 |
Why?
|
Samarium | 1 | 2012 | 3 | 0.110 |
Why?
|
Indoles | 1 | 2021 | 1833 | 0.110 |
Why?
|
Life Expectancy | 1 | 2019 | 1242 | 0.100 |
Why?
|
Drug Approval | 1 | 2020 | 814 | 0.100 |
Why?
|
Clodronic Acid | 1 | 2012 | 59 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3086 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3206 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14607 | 0.100 |
Why?
|
Radioisotopes | 2 | 2024 | 499 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5492 | 0.100 |
Why?
|
Absorptiometry, Photon | 2 | 2023 | 1738 | 0.100 |
Why?
|
Postpartum Hemorrhage | 1 | 2016 | 272 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10212 | 0.100 |
Why?
|
DNA Repair | 1 | 2021 | 2046 | 0.100 |
Why?
|
Testicular Neoplasms | 1 | 2018 | 799 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4251 | 0.100 |
Why?
|
Comparative Effectiveness Research | 2 | 2014 | 709 | 0.090 |
Why?
|
Patient Care Team | 1 | 2022 | 2521 | 0.090 |
Why?
|
DNA Damage | 1 | 2021 | 2449 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2018 | 815 | 0.090 |
Why?
|
Truth Disclosure | 1 | 2015 | 434 | 0.090 |
Why?
|
Fractures, Spontaneous | 1 | 2012 | 231 | 0.090 |
Why?
|
Intensive Care Units | 1 | 2024 | 3744 | 0.090 |
Why?
|
Time Factors | 5 | 2020 | 39970 | 0.090 |
Why?
|
Colonic Neoplasms | 1 | 2022 | 2538 | 0.090 |
Why?
|
Self Report | 2 | 2019 | 3725 | 0.090 |
Why?
|
Incidence | 5 | 2019 | 21355 | 0.090 |
Why?
|
Hip | 1 | 2012 | 255 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2023 | 12463 | 0.090 |
Why?
|
Length of Stay | 1 | 2024 | 6426 | 0.090 |
Why?
|
Patient Satisfaction | 1 | 2023 | 3461 | 0.090 |
Why?
|
Double-Blind Method | 1 | 2024 | 12341 | 0.090 |
Why?
|
Nephrectomy | 1 | 2015 | 937 | 0.090 |
Why?
|
Gene Deletion | 1 | 2017 | 2665 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2319 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39107 | 0.080 |
Why?
|
Intestinal Diseases | 1 | 2014 | 504 | 0.080 |
Why?
|
Platelet Adhesiveness | 1 | 2009 | 154 | 0.080 |
Why?
|
Age Factors | 5 | 2024 | 18398 | 0.080 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1410 | 0.080 |
Why?
|
Intercellular Junctions | 1 | 2009 | 195 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2875 | 0.080 |
Why?
|
Pain | 3 | 2023 | 5073 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1422 | 0.080 |
Why?
|
Valsalva Maneuver | 1 | 2009 | 99 | 0.080 |
Why?
|
Databases, Factual | 2 | 2021 | 7967 | 0.080 |
Why?
|
Lymph Nodes | 2 | 2018 | 3466 | 0.080 |
Why?
|
Osteoclasts | 1 | 2012 | 711 | 0.080 |
Why?
|
Data Collection | 2 | 2014 | 3322 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1998 | 0.070 |
Why?
|
Models, Biological | 1 | 2024 | 9469 | 0.070 |
Why?
|
Ablation Techniques | 2 | 2020 | 248 | 0.070 |
Why?
|
Pain Measurement | 1 | 2018 | 3551 | 0.070 |
Why?
|
Diphosphonates | 1 | 2012 | 635 | 0.070 |
Why?
|
Affect | 1 | 2015 | 1486 | 0.070 |
Why?
|
Placebos | 1 | 2012 | 1667 | 0.070 |
Why?
|
Complementary Therapies | 1 | 2011 | 486 | 0.070 |
Why?
|
Societies, Medical | 4 | 2020 | 3905 | 0.070 |
Why?
|
Pancreatectomy | 1 | 2011 | 811 | 0.070 |
Why?
|
Health Status | 1 | 2019 | 4077 | 0.070 |
Why?
|
Tachycardia | 1 | 2009 | 600 | 0.070 |
Why?
|
Pandemics | 3 | 2022 | 8656 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2024 | 5336 | 0.070 |
Why?
|
Imidazoles | 1 | 2012 | 1180 | 0.070 |
Why?
|
Urinary Bladder | 2 | 2023 | 1152 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8466 | 0.060 |
Why?
|
Adult | 11 | 2024 | 221203 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9280 | 0.060 |
Why?
|
Femur | 1 | 2012 | 1307 | 0.060 |
Why?
|
Platelet Activation | 2 | 2009 | 645 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2023 | 21017 | 0.060 |
Why?
|
Spine | 1 | 2012 | 1118 | 0.060 |
Why?
|
Body Mass Index | 1 | 2022 | 12954 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5305 | 0.060 |
Why?
|
Heart Neoplasms | 1 | 2007 | 362 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 9646 | 0.060 |
Why?
|
Health Promotion | 1 | 2015 | 2214 | 0.050 |
Why?
|
Heart | 1 | 2016 | 4404 | 0.050 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 1601 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2015 | 1852 | 0.050 |
Why?
|
Medicare | 1 | 2021 | 6770 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3052 | 0.050 |
Why?
|
Injections, Intramuscular | 1 | 2024 | 554 | 0.050 |
Why?
|
Salivary Glands | 1 | 2024 | 229 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 681 | 0.050 |
Why?
|
Risk | 1 | 2014 | 9610 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9031 | 0.050 |
Why?
|
Indazoles | 1 | 2024 | 304 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20571 | 0.050 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3530 | 0.050 |
Why?
|
Kidney | 1 | 2016 | 7047 | 0.050 |
Why?
|
Communication | 1 | 2015 | 3873 | 0.050 |
Why?
|
Liver | 1 | 2016 | 7529 | 0.050 |
Why?
|
Platelet Aggregation | 1 | 2004 | 771 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13510 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2021 | 111 | 0.040 |
Why?
|
Nomograms | 1 | 2022 | 230 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3165 | 0.040 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9177 | 0.040 |
Why?
|
Female | 12 | 2024 | 392686 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3358 | 0.040 |
Why?
|
San Francisco | 1 | 2019 | 162 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
Blood Pressure | 2 | 2016 | 8481 | 0.040 |
Why?
|
Oligopeptides | 1 | 2024 | 1187 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5672 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3688 | 0.040 |
Why?
|
Comorbidity | 3 | 2020 | 10508 | 0.040 |
Why?
|
Hypogonadism | 1 | 2024 | 798 | 0.040 |
Why?
|
Blood Coagulation | 1 | 2004 | 1154 | 0.040 |
Why?
|
Thrombosis | 2 | 2009 | 2942 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26127 | 0.040 |
Why?
|
Markov Chains | 1 | 2021 | 966 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2007 | 1405 | 0.040 |
Why?
|
Organizational Innovation | 1 | 2020 | 537 | 0.040 |
Why?
|
Bleomycin | 1 | 2018 | 494 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1923 | 0.040 |
Why?
|
Etoposide | 1 | 2018 | 634 | 0.030 |
Why?
|
Kallikreins | 1 | 2018 | 220 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 634 | 0.030 |
Why?
|
American Heart Association | 1 | 2021 | 1039 | 0.030 |
Why?
|
Melanoma | 1 | 2015 | 5709 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Logistic Models | 2 | 2024 | 13255 | 0.030 |
Why?
|
Heart Function Tests | 1 | 2016 | 318 | 0.030 |
Why?
|
Signal Transduction | 3 | 2024 | 23447 | 0.030 |
Why?
|
Piperidines | 1 | 2024 | 1656 | 0.030 |
Why?
|
Advisory Committees | 1 | 2019 | 787 | 0.030 |
Why?
|
Genetic Counseling | 1 | 2019 | 627 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 523 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2019 | 567 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12975 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 679 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 946 | 0.030 |
Why?
|
Pituitary Diseases | 1 | 2015 | 135 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 846 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5369 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2019 | 836 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2020 | 1264 | 0.030 |
Why?
|
Blood Platelets | 1 | 2004 | 2479 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2015 | 410 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2047 | 0.030 |
Why?
|
Prevalence | 2 | 2023 | 15732 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2767 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 2021 | 1159 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 3615 | 0.020 |
Why?
|
Uterus | 1 | 2016 | 649 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2024 | 10766 | 0.020 |
Why?
|
Remission Induction | 2 | 2008 | 2397 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2865 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2004 | 4513 | 0.020 |
Why?
|
Pruritus | 1 | 2015 | 380 | 0.020 |
Why?
|
Biopsy | 1 | 2022 | 6766 | 0.020 |
Why?
|
Health Expenditures | 1 | 2023 | 2366 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2917 | 0.020 |
Why?
|
Exanthema | 1 | 2015 | 503 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2017 | 1530 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3597 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2281 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3683 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2880 | 0.020 |
Why?
|
Exercise | 2 | 2016 | 5890 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2015 | 1787 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2827 | 0.020 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 1141 | 0.020 |
Why?
|
Neuralgia | 1 | 2015 | 615 | 0.020 |
Why?
|
Diarrhea | 1 | 2015 | 1318 | 0.020 |
Why?
|
Medical Records | 1 | 2013 | 1408 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3060 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8224 | 0.020 |
Why?
|
Sleep | 1 | 2022 | 4768 | 0.020 |
Why?
|
Hemostasis | 1 | 2009 | 467 | 0.020 |
Why?
|
Cholesterol | 1 | 2016 | 2904 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3808 | 0.020 |
Why?
|
Mass Screening | 1 | 2022 | 5428 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4740 | 0.020 |
Why?
|
Colitis | 1 | 2015 | 1233 | 0.020 |
Why?
|
Mental Health | 1 | 2020 | 3250 | 0.020 |
Why?
|
Pressure | 1 | 2009 | 1154 | 0.020 |
Why?
|
Vincristine | 1 | 2007 | 1036 | 0.020 |
Why?
|
Regression Analysis | 1 | 2014 | 6344 | 0.010 |
Why?
|
Posture | 1 | 2009 | 957 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 694 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6484 | 0.010 |
Why?
|
Bleeding Time | 1 | 2004 | 83 | 0.010 |
Why?
|
Aspirin | 1 | 2016 | 3133 | 0.010 |
Why?
|
Phenotype | 1 | 2022 | 16592 | 0.010 |
Why?
|
Young Adult | 2 | 2024 | 59255 | 0.010 |
Why?
|
Life Style | 1 | 2015 | 3917 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2015 | 2057 | 0.010 |
Why?
|
Linear Models | 1 | 2014 | 5872 | 0.010 |
Why?
|
Protein Transport | 1 | 2009 | 1967 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2011 | 2915 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2007 | 2220 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10553 | 0.010 |
Why?
|
Doxorubicin | 1 | 2007 | 2224 | 0.010 |
Why?
|
Fibrinogen | 1 | 2004 | 888 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2004 | 1699 | 0.010 |
Why?
|
Survival Analysis | 1 | 2011 | 10090 | 0.010 |
Why?
|
Diet | 1 | 2015 | 8075 | 0.010 |
Why?
|
Lung Diseases | 1 | 2007 | 1909 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4001 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 30054 | 0.010 |
Why?
|
Child | 1 | 2024 | 80156 | 0.010 |
Why?
|
Hypertension | 1 | 2015 | 8540 | 0.010 |
Why?
|
Adolescent | 1 | 2024 | 88324 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2004 | 2456 | 0.010 |
Why?
|
Echocardiography | 1 | 2007 | 4989 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2008 | 3801 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2009 | 14416 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29876 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 6485 | 0.010 |
Why?
|
Mice | 2 | 2009 | 81533 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2004 | 12794 | 0.000 |
Why?
|
Animals | 2 | 2009 | 168467 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 36429 | 0.000 |
Why?
|